- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.01. | Teva lines up $500M in Royalty Pharma funding for vitiligo drug | ||
| 12.01. | Eikon next in line for IPO, with funds set to bankroll clutch of clinical cancer drugs | ||
| 09.01. | 3 new venture funds collect nearly $1B for biotech in US, EU | ||
| 09.01. | AirNexis takes flight with $200M, links up with China pharma for COPD asset in $955M biobucks deal | ||
| 09.01. | Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential | ||
| 09.01. | Baby KJ scientist launches personalized CRISPR therapy startup | ||
| 09.01. | Roche returns to MediLink with promise of $570M near-term payments for another ADC | ||
| 09.01. | 1st biotech IPO of 2026 sees Aktis bring in $318M via upsized offering | ||
| 08.01. | Ollin eyes phase 3 after bispecific tops Vabysmo in early-stage trial, clearing more retinal disease faster | ||
| 08.01. | GSK inks a model deal in $50M bet on Noetik's cancer AI platform | ||
| 08.01. | Flagship-founded Tessera plans to lay off 90 employees in March | ||
| 08.01. | J&J, Google venture arms line up to back protein degradation biotech EpiBiologics' $107M series B | ||
| 08.01. | Foresee offloads MMP-12 inhibitors in $584M deal, focuses on Camcevi's potential | ||
| 08.01. | Lilly buys inflammation biotech Venytx for $1.2B in wake of Parkinson's, CV readouts | ||
| 08.01. | Immuneering touts 64% 1-year survival, keeping wheels turning in race with Revolution | ||
| 07.01. | Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M | ||
| 07.01. | Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate | ||
| 07.01. | Amgen dances with Disco in $618M cancer target pact | ||
| 07.01. | Rakuten lights path to 2028 FDA filing with fresh $100M raise | ||
| 07.01. | Soley secures $200M series C to push AML cell stress drug into clinic | ||
| 07.01. | Basilea pens collab with US biotech to develop new antifungal | ||
| 07.01. | GSK's 'functional cure' for hep B proves worth in phase 3 trials setting up approval push | ||
| 07.01. | Hutchmed heats up autoimmune race with phase 3 win, teeing up China filing | ||
| 06.01. | Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact | ||
| 06.01. | Bright Minds shines with phase 2 win for anti-seizure serotonin receptor activator |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.